None listed
Conditions
Interventions
Drug : LY2140023 (5 mg BID, 40 mg BID or 80 mg BID , oral.
Sponsors
Eli Lilly Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1] Patients are males or females, 20 to 65 years of age (inclusive) at study entry, with a diagnosis of schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; APA 2000) (Disorganized, 295.10; Catatonic, 295.20; Paranoid 295.30; or Undifferentiated, 295.90) and confirmed by the Structured Clinical Interview for DSM-IV-TR (SCID) at Visit 1.
Exclusion criteria
Exclusion criteria: [1] Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. [2] Are Lilly employees. [3] Have any other current Axis I psychiatric diagnoses (as defined in DSM-IV-TR) in addition to schizophrenia. [4] Have participated in any clinical trial with any pharmacological treatment intervention for which they received a study-related medication in the 6 months prior to Visit 1. [5] Have previously completed or withdrawn from this study, or any other study investigating LY2140023 or any predecessor molecules with glutamatergic activity. [6] Are patients for whom treatment with LY2140023 or placebo, as specified in this protocol, is relatively or absolutely clinically contraindicated.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI) | — |
Countries
Korea, Republic of
Contacts
Public ContactJung Sik Lee
Medical Foundation Yong-in Mental Hospital
Outcome results
None listed